Unknown

Dataset Information

Scientifically based combination therapies with immuno-oncology checkpoint inhibitors.


ABSTRACT: The discovery of immune checkpoints and their role in modulating immune response have revolutionised cancer treatment in recent years. The immune checkpoints, cytotoxic T-lymphocyte-associated protein 4, programmed cell death protein 1 and its ligand, programmed cell death-ligand 1, have been extensively studied. Currently 7 monoclonal antibodies targeting these immune checkpoints are approved for treatment of various cancers. Inhibiting immune checkpoints has shown some success in clinic, however, a proportion of patients do not benefit from this treatment. Several other inhibitory molecules, in addition to lymphocyte-associated protein 4 and programmed cell death protein 1, are known to be involved in regulating immune response. To further improve patient outcomes, studies have examined

SUBMITTER: Chew HY 

PROVIDER: S-EPMC7444785 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature